Comparison of Two Non-invasive Neuromodulation Techniques as Synergistic Therapy to Cognitive Stimulation in Amnestic Mild Cognitive Impairment (aMCI)
NCT06467253, Not applicable, Recruiting, Instituto Nacional de Psiquiatría Dr. Ramón de la Fuente
Trial 10
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
| Field | Value | Source |
|---|---|---|
| Title | Comparison of Two Non-invasive Neuromodulation Techniques as Synergistic Therapy to Cognitive Stimulation in Amnestic Mild Cognitive Impairment (aMCI) | ClinicalTrials.gov |
| NCT number | NCT06467253 | ClinicalTrials.gov |
| Status | Recruiting | ClinicalTrials.gov |
| Phases | Not applicable | ClinicalTrials.gov |
| Enrollment | 60 participants, estimated | ClinicalTrials.gov |
| Lead sponsor | Instituto Nacional de Psiquiatría Dr. Ramón de la Fuente | ClinicalTrials.gov |
| Conditions | Mild Cognitive Impairment | ClinicalTrials.gov |
| Interventions | 1. rTMS + CS, 2. rTMS Sham + CS, 3. tDCS + CS, 4. tDCS Sham + CS | ClinicalTrials.gov |
| First posted | 2024-06-20 | ClinicalTrials.gov |
| Last updated | 2024-06-20 | ClinicalTrials.gov |
Registered outcomes 29
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description | Source |
|---|---|---|---|---|
| Primary | Changes in orientation | Baseline, after maintenance (15 weeks), and in follow-up phase (1 year later). | Measured by the Barcelona Test. Score ranges from 10 or less to 95. Direct scores are converted to percentile. Higher scores mean better outcomes. | ClinicalTrials.gov |
| Primary | Changes in language | Baseline, after maintenance (15 weeks), and in follow-up phase (1 year later). | Measured by the WAIS-IV vocabulary test. Score ranges from 1 to 19. Direct scores are converted to standardized scores. Higher scores mean better outcomes. | ClinicalTrials.gov |
| Primary | Changes in language | Baseline, after maintenance (15 weeks), and in follow-up phase (1 year later). | Measured by the Barcelona Test. Score ranges from 10 or less to 95. Direct scores are converted to percentile. Higher scores mean better outcomes. | ClinicalTrials.gov |
| Primary | Changes in verbal memory | Baseline, after maintenance (15 weeks), and in follow-up phase (1 year later). | Measured by the Barcelona Test. Score ranges from 10 or less to 95. Direct scores are converted to percentile. Higher scores mean better outcomes. | ClinicalTrials.gov |
| Primary | Changes in verbal memory | Baseline, after maintenance (15 weeks), and in follow-up phase (1 year later). | Measured by Neuropsi Attention and Memory. Score ranges from 1 to 19. Direct scores are converted to standardized scores. Higher scores mean better outcomes. | ClinicalTrials.gov |
| Primary | Changes in visual memory | Baseline, after maintenance (15 weeks), and in follow-up phase (1 year later). | Measured by the Barcelona Test. Score ranges from 10 or less to 95. Direct scores are converted to percentile. Higher scores mean better outcomes. | ClinicalTrials.gov |
| Primary | Changes in visual memory | Baseline, after maintenance (15 weeks), and in follow-up phase (1 year later). | Measured by Neuropsi Attention and Memory. Score ranges from 1 to 19. Direct scores are converted to standardized scores. Higher scores mean better outcomes. | ClinicalTrials.gov |
| Primary | Changes in visual-constructive abilities | Baseline, after maintenance (15 weeks), and in follow-up phase (1 year later). | Measured by the Barcelona Test. Score ranges from 10 or less to 95. Direct scores are converted to percentile. Higher scores mean better outcomes. | ClinicalTrials.gov |
| Primary | Changes in visual-constructive abilities | Baseline, after maintenance (15 weeks), and in follow-up phase (1 year later). | Measured by Neuropsi Attention and Memory. Score ranges from 10 or less to 95. Direct scores are converted to standardized scores. Higher scores mean better outcomes. | ClinicalTrials.gov |
| Primary | Changes in processing speed | Baseline, after maintenance (15 weeks), and in follow-up phase (1 year later). | Measured by the Barcelona Test. Score ranges from 10 or less to 95. Direct scores are converted to percentile. Higher scores mean better outcomes. | ClinicalTrials.gov |
| Primary | Changes in processing speed | Baseline, after maintenance (15 weeks), and in follow-up phase (1 year later). | Measured by the Trail Making Test version A and B. Score ranges from 5 to 95. Direct scores are converted to percentile. Higher scores mean better outcomes. | ClinicalTrials.gov |
| Primary | Changes in abstraction | Baseline, after maintenance (15 weeks), and in follow-up phase (1 year later). | Measured by the Barcelona Test. Score ranges from 10 or less to 95. Direct scores are converted to percentile. Higher scores mean better outcomes. | ClinicalTrials.gov |
| Primary | Changes in verbal fluency | Baseline, after maintenance (15 weeks), and in follow-up phase (1 year later). | Measured by a verbal fluency test (semantic: animals and phonologic: F, A, S). Score ranges from 5 to 95. Direct scores are converted to percentile. Higher scores mean better outcomes. | ClinicalTrials.gov |
| Primary | Changes in interference | Baseline, after maintenance (15 weeks), and in follow-up phase (1 year later). | Measured by the Stroop Test. Score ranges from 5 to 95. Direct scores are converted to percentile. Higher scores mean better outcomes. | ClinicalTrials.gov |
| Primary | Changes in working memory | Baseline, after maintenance (15 weeks), and in follow-up phase (1 year later). | Measured by the Barcelona Test. Score ranges from 10 or less to 95. Direct scores are converted to percentile. Higher scores mean better outcomes. | ClinicalTrials.gov |
| Primary | Changes in working memory | Baseline, after maintenance (15 weeks), and in follow-up phase (1 year later). | Measured by Trail Making Test version A and B. Score ranges from 5 to 95. Direct scores are converted to percentile. Higher scores mean better outcomes. | ClinicalTrials.gov |
| Primary | Changes in Global Cognitive Function | Baseline, after first phase (3 weeks), after maintenance (15 weeks) and in follow-up phase (1 year later). | Measured by Montreal Cognitive Assessment. Score ranges from 0 to 30 points. Higher scores mean better outcomes. | ClinicalTrials.gov |
| Primary | Changes in Global Cognitive Function | Baseline, after first phase (3 weeks), after maintenance (15 weeks) and in follow-up phase (1 year later). | Measured by Screen for Cognitive Impairment in Psychiatry. Direct scores ranges from 37 to 115 points. Higher scores mean better outcomes. | ClinicalTrials.gov |
| Primary | Changes in memory regarding situations and activities of daily life | Baseline, after first phase (3 weeks), after maintenance (15 weeks) and in follow-up phase (1 year later) | Measure by Everyday Memory Questionnaire. Score ranges from 0 to 56. Higher scores mean worse outcomes. | ClinicalTrials.gov |
| Primary | Changes in Global Clinical Impression | Baseline, after first phase (3 weeks), after maintenance (15 weeks) and in follow-up phase (1 year later). | Measure by Clinical Impression Scale. Score ranges from 0 to 7. Higher scores mean worse outcomes. | ClinicalTrials.gov |
Outcomes 0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as | Source |
|---|
Results by group 0
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units | Source |
|---|
Participant flow 0
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted | Source |
|---|
Adverse events 0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events | Source |
|---|
Adverse event totals 0
The totals the trial posted for each group.
| Total | Group | Affected | At risk | Source |
|---|
Papers 0
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as | Source |
|---|
Grants 0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years | Source |
|---|
Trial comparisons 0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|
Tests 5
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
| Test | Named as | Source |
|---|---|---|
| Sternberg Memory Scanning | Primary outcome | ConductCognition |
| Stroop Color-Word Test | Primary outcome | ConductCognition |
| Trail Making Test A | Primary outcome | ConductCognition |
| Trail Making Test B | Primary outcome | ConductCognition |
| Verbal Fluency | Primary outcome | ConductCognition |
Source 5
| Field | Value | Source |
|---|---|---|
| Release | trials-2026-11-12-0.4.0 | ClinicalTrials.gov |
| Release manifest SHA-256 | 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4 | ClinicalTrials.gov |
| Registry capture | 2026-11-12 | ClinicalTrials.gov |
| Results copy, AACT | 2026-03-23 | ClinicalTrials.gov |
| NIH clinical studies file | 2026-11-13 | ClinicalTrials.gov |
Release trials-2026-11-12-0.4.0
ClinicalTrials.gov's posted results, through CTTI's AACT: ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299 ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
ClinicalTrials.gov: none stated ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
NIH RePORTER's clinical studies and project files: Public domain (NIH RePORTER)